News – Page 1045 – Endpoints News

FDA orders a partial hold on Epizyme’s lead cancer drug tazemetostat following T-cell lymphoma case

8 years ago

FDA panel offers a wavering thumbs up for Eli Lilly's 2 mg baricitinib, thumbs down on 4 mg

8 years ago

Bankrupt and weary, diet pill maker Orexigen to sell for $75M to Nalpropion

8 years ago

The under-40s: How does the next generation of biopharma executives view the future?

8 years ago

Sanofi loses its German CSO and diabetes chief to Grünenthal; Roche touts longterm advantages of Ocrevus in treating ...

8 years ago

EMA committee recommends Alnylam's early-stage ATTR amyloidosis drug for orphan status

8 years ago

Pfizer hits stumbling block on Herceptin rival, but wins 'breakthrough' status on MenB vaccine

8 years ago

Sage files for an approval for its ‘breakthrough’ therapy for postpartum depression

8 years ago

Penny stock biotech Synthetic Biologics sees its 'breakthrough' status pulled as FDA ponders safety issues

8 years ago

Prothena’s lead drug NEOD001 just imploded in 2 late-stage studies — and there’s nothing left to salvage

8 years ago

Dicerna shares rocket up on a $15M-plus-stock deal to settle Alnylam claims — will deals follow?

8 years ago

After fruitless talks, a bid from Vas and plenty of patience, AveXis CEO Sean Nolan slowly reeled in an $8.7B deal

8 years ago

Pressing for direct negotiations, Takeda adds cash to a meatier $63B bid to buy Shire

8 years ago

Hong Kong clears way for pre-revenue biotech IPOs, plans to accept listing applications by May

8 years ago

Arcturus takes another legal stab at former CEO as public battle turns serious for the company

8 years ago

John Orwin tapped to lead Atreca; John Tsai takes Vas Narasimhan's old role at Novartis; Hal Barron nabs Genentech's ...

8 years ago

Novartis CEO Vas Narasimhan is raising the bar on second-gen cancer drug studies

8 years ago

With Gilenya generics looming, Novartis’ siponimod team buffs up the MS data package being prepped for the FDA

8 years ago

CHMP scolds AB Science (again) for masitinib shortcomings, triggering a new rout on stock price

8 years ago

UCB snags an NDA-ready epilepsy drug from Proximagen in $370M deal

8 years ago

Biogen pays $1B cash to enlist Ionis on a new drug discovery campaign — but can it deliver fast enough for ...

8 years ago

On second thought, Allergan doesn't want to consider a bid for Shire, leaving Takeda in sole pursuit of $62.5B deal

8 years ago

GW Pharma walks away from adcomm with unanimous support for anti-seizure med. An OK shouldn’t take long now

8 years ago

Tocagen licenses immunotherapy to ApolloBio for $16M upfront; WuXi AppTec unveils expanded lab testing site in New ...

8 years ago

First page Previous page 1042 1043 104410451046 1047 1048 Next page Last page